These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 8939142)
1. Use of interferon beta 1b for multiple sclerosis. Importance of relapses must not be underestimated. Cardy P BMJ; 1996 Nov; 313(7067):1263. PubMed ID: 8939142 [No Abstract] [Full Text] [Related]
3. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis. Petkau J; White R Mult Scler; 1997 Dec; 3(6):402. PubMed ID: 9493643 [No Abstract] [Full Text] [Related]
4. Use of interferon beta 1b for multiple sclerosis. Manufacturer defends the drug. Longthorne PN BMJ; 1996 Nov; 313(7067):1263. PubMed ID: 8939141 [No Abstract] [Full Text] [Related]
5. Treatment of multiple sclerosis with interferon beta-1 b. Abdul-Ahad A; Shah S; Galazka A Neurology; 1997 Aug; 49(2):641-2. PubMed ID: 9270626 [No Abstract] [Full Text] [Related]
6. Use of interferon beta 1b for multiple sclerosis. Patients will put up with side effects because of their desire to beat the disease. Chellingsworth M BMJ; 1996 Nov; 313(7067):1263. PubMed ID: 8939140 [No Abstract] [Full Text] [Related]
7. Why interferon beta 1b was licensed is a mystery. Harvey P BMJ; 1996 Aug; 313(7052):297-8. PubMed ID: 8704553 [No Abstract] [Full Text] [Related]
8. [Immunotherapy of multiple sclerosis. Consensus and controversies]. Hohlfeld R Nervenarzt; 1999 Apr; 70(4):297. PubMed ID: 10354989 [No Abstract] [Full Text] [Related]
9. Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment. Blake G; Murphy S Neurology; 1997 Dec; 49(6):1747-8. PubMed ID: 9409387 [No Abstract] [Full Text] [Related]
10. Multiple sclerosis and interferon beta-1b, past, present and future. Horowski R Clin Neurol Neurosurg; 2002 Jul; 104(3):259-64. PubMed ID: 12127665 [No Abstract] [Full Text] [Related]
11. New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson. Alsalameh S; Manger B; Kern P; Kalden J Arthritis Rheum; 1998 Apr; 41(4):754. PubMed ID: 9550494 [No Abstract] [Full Text] [Related]
12. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b. Frese A; Bethke F; Lüdemann P; Stögbauer F Neurology; 1999 Nov; 53(8):1892-3. PubMed ID: 10563657 [No Abstract] [Full Text] [Related]
15. The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis. Schwartz CE; Coulthard-Morris L; Cole B; Vollmer T Arch Neurol; 1997 Dec; 54(12):1475-80. PubMed ID: 9400356 [TBL] [Abstract][Full Text] [Related]
16. Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist. Pachner AR Neurology; 1997 Sep; 49(3):647-50. PubMed ID: 9305316 [No Abstract] [Full Text] [Related]
18. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. Webster GF; Knobler RL; Lublin FD; Kramer EM; Hochman LR J Am Acad Dermatol; 1996 Feb; 34(2 Pt 2):365-7. PubMed ID: 8655728 [TBL] [Abstract][Full Text] [Related]
19. Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b). Nicoletti F; Di Marco R; Patti F; Reggio E; Nicoletti A; Zaccone P; Stivala F; Meroni PL; Reggio A Clin Exp Immunol; 1998 Jul; 113(1):96-9. PubMed ID: 9697990 [TBL] [Abstract][Full Text] [Related]
20. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta. Rice G Arch Neurol; 2001 Aug; 58(8):1297-8. PubMed ID: 11493173 [No Abstract] [Full Text] [Related] [Next] [New Search]